Can melatonin reduce the severity of COVID-19 pandemic?
Identifieur interne : 000016 ( PubMed/Curation ); précédent : 000015; suivant : 000017Can melatonin reduce the severity of COVID-19 pandemic?
Auteurs : Alex Shneider [États-Unis] ; Aleksandr Kudriavtsev [Russie] ; Anna Vakhrusheva [Russie]Source :
- International reviews of immunology [ 1563-5244 ] ; 2020.
Abstract
The current COVID-19 pandemic is one of the most devastating events in recent history. The virus causes relatively minor damage to young, healthy populations, imposing life-threatening danger to the elderly and people with diseases of chronic inflammation. Therefore, if we could reduce the risk for vulnerable populations, it would make the COVID-19 pandemic more similar to other typical outbreaks. Children don't suffer from COVID-19 as much as their grandparents and have a much higher melatonin level. Bats are nocturnal animals possessing high levels of melatonin, which may contribute to their high anti-viral resistance. Viruses induce an explosion of inflammatory cytokines and reactive oxygen species, and melatonin is the best natural antioxidant that is lost with age. The programmed cell death coronaviruses cause, which can result in significant lung damage, is also inhibited by melatonin. Coronavirus causes inflammation in the lungs which requires inflammasome activity. Melatonin blocks these inflammasomes. General immunity is impaired by anxiety and sleep deprivation. Melatonin improves sleep habits, reduces anxiety and stimulates immunity. Fibrosis may be the most dangerous complication after COVID-19. Melatonin is known to prevent fibrosis. Mechanical ventilation may be necessary but yet imposes risks due to oxidative stress, which can be reduced by melatonin. Thus, by using the safe over-the-counter drug melatonin, we may be immediately able to prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients' health after the active phase of the infection is over.
DOI: 10.1080/08830185.2020.1756284
PubMed: 32347747
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000016
Links to Exploration step
pubmed:32347747Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Can melatonin reduce the severity of COVID-19 pandemic?</title>
<author><name sortKey="Shneider, Alex" sort="Shneider, Alex" uniqKey="Shneider A" first="Alex" last="Shneider">Alex Shneider</name>
<affiliation wicri:level="1"><nlm:affiliation>CureLab Oncology, Inc, Dedham, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>CureLab Oncology, Inc, Dedham, Massachusetts</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kudriavtsev, Aleksandr" sort="Kudriavtsev, Aleksandr" uniqKey="Kudriavtsev A" first="Aleksandr" last="Kudriavtsev">Aleksandr Kudriavtsev</name>
<affiliation wicri:level="1"><nlm:affiliation>Biological Faculty, Lomonosov Moscow State University, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Biological Faculty, Lomonosov Moscow State University, Moscow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vakhrusheva, Anna" sort="Vakhrusheva, Anna" uniqKey="Vakhrusheva A" first="Anna" last="Vakhrusheva">Anna Vakhrusheva</name>
<affiliation wicri:level="1"><nlm:affiliation>Biological Faculty, Lomonosov Moscow State University, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Biological Faculty, Lomonosov Moscow State University, Moscow</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32347747</idno>
<idno type="pmid">32347747</idno>
<idno type="doi">10.1080/08830185.2020.1756284</idno>
<idno type="wicri:Area/PubMed/Corpus">000016</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000016</idno>
<idno type="wicri:Area/PubMed/Curation">000016</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000016</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Can melatonin reduce the severity of COVID-19 pandemic?</title>
<author><name sortKey="Shneider, Alex" sort="Shneider, Alex" uniqKey="Shneider A" first="Alex" last="Shneider">Alex Shneider</name>
<affiliation wicri:level="1"><nlm:affiliation>CureLab Oncology, Inc, Dedham, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>CureLab Oncology, Inc, Dedham, Massachusetts</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kudriavtsev, Aleksandr" sort="Kudriavtsev, Aleksandr" uniqKey="Kudriavtsev A" first="Aleksandr" last="Kudriavtsev">Aleksandr Kudriavtsev</name>
<affiliation wicri:level="1"><nlm:affiliation>Biological Faculty, Lomonosov Moscow State University, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Biological Faculty, Lomonosov Moscow State University, Moscow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vakhrusheva, Anna" sort="Vakhrusheva, Anna" uniqKey="Vakhrusheva A" first="Anna" last="Vakhrusheva">Anna Vakhrusheva</name>
<affiliation wicri:level="1"><nlm:affiliation>Biological Faculty, Lomonosov Moscow State University, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Biological Faculty, Lomonosov Moscow State University, Moscow</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">International reviews of immunology</title>
<idno type="eISSN">1563-5244</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The current COVID-19 pandemic is one of the most devastating events in recent history. The virus causes relatively minor damage to young, healthy populations, imposing life-threatening danger to the elderly and people with diseases of chronic inflammation. Therefore, if we could reduce the risk for vulnerable populations, it would make the COVID-19 pandemic more similar to other typical outbreaks. Children don't suffer from COVID-19 as much as their grandparents and have a much higher melatonin level. Bats are nocturnal animals possessing high levels of melatonin, which may contribute to their high anti-viral resistance. Viruses induce an explosion of inflammatory cytokines and reactive oxygen species, and melatonin is the best natural antioxidant that is lost with age. The programmed cell death coronaviruses cause, which can result in significant lung damage, is also inhibited by melatonin. Coronavirus causes inflammation in the lungs which requires inflammasome activity. Melatonin blocks these inflammasomes. General immunity is impaired by anxiety and sleep deprivation. Melatonin improves sleep habits, reduces anxiety and stimulates immunity. Fibrosis may be the most dangerous complication after COVID-19. Melatonin is known to prevent fibrosis. Mechanical ventilation may be necessary but yet imposes risks due to oxidative stress, which can be reduced by melatonin. Thus, by using the safe over-the-counter drug melatonin, we may be immediately able to prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients' health after the active phase of the infection is over.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32347747</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1563-5244</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>29</Day>
</PubDate>
</JournalIssue>
<Title>International reviews of immunology</Title>
<ISOAbbreviation>Int. Rev. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Can melatonin reduce the severity of COVID-19 pandemic?</ArticleTitle>
<Pagination><MedlinePgn>1-10</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/08830185.2020.1756284</ELocationID>
<Abstract><AbstractText>The current COVID-19 pandemic is one of the most devastating events in recent history. The virus causes relatively minor damage to young, healthy populations, imposing life-threatening danger to the elderly and people with diseases of chronic inflammation. Therefore, if we could reduce the risk for vulnerable populations, it would make the COVID-19 pandemic more similar to other typical outbreaks. Children don't suffer from COVID-19 as much as their grandparents and have a much higher melatonin level. Bats are nocturnal animals possessing high levels of melatonin, which may contribute to their high anti-viral resistance. Viruses induce an explosion of inflammatory cytokines and reactive oxygen species, and melatonin is the best natural antioxidant that is lost with age. The programmed cell death coronaviruses cause, which can result in significant lung damage, is also inhibited by melatonin. Coronavirus causes inflammation in the lungs which requires inflammasome activity. Melatonin blocks these inflammasomes. General immunity is impaired by anxiety and sleep deprivation. Melatonin improves sleep habits, reduces anxiety and stimulates immunity. Fibrosis may be the most dangerous complication after COVID-19. Melatonin is known to prevent fibrosis. Mechanical ventilation may be necessary but yet imposes risks due to oxidative stress, which can be reduced by melatonin. Thus, by using the safe over-the-counter drug melatonin, we may be immediately able to prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients' health after the active phase of the infection is over.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shneider</LastName>
<ForeName>Alex</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-2150-6727</Identifier>
<AffiliationInfo><Affiliation>CureLab Oncology, Inc, Dedham, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Molecular Biology, Ariel University, Ariel, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kudriavtsev</LastName>
<ForeName>Aleksandr</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-3918-5618</Identifier>
<AffiliationInfo><Affiliation>Biological Faculty, Lomonosov Moscow State University, Moscow, Russia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Emanuel Institute of Biochemical Phisics, RAS, Moscow, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vakhrusheva</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-7948-1254</Identifier>
<AffiliationInfo><Affiliation>Biological Faculty, Lomonosov Moscow State University, Moscow, Russia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Int Rev Immunol</MedlineTA>
<NlmUniqueID>8712260</NlmUniqueID>
<ISSNLinking>0883-0185</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">Bat</Keyword>
<Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">Melatonin</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32347747</ArticleId>
<ArticleId IdType="doi">10.1080/08830185.2020.1756284</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000016 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000016 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= StressCovidV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:32347747 |texte= Can melatonin reduce the severity of COVID-19 pandemic? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32347747" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a StressCovidV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |